Akebia Therapeutics (AKBA) Cash from Operations (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Cash from Operations data on file, last reported at 21207000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 56.08% year-over-year to 21207000.0 in Q1 2026; TTM through Mar 2026 was 60372000.0, a 273.41% increase from a year earlier, with the FY2025 full-year figure at 67992000.0, up 267.22% from the prior year.
• Cash from Operations for Q1 2026 stood at 21207000.0, down from 31129000.0 in the prior quarter.
• Over the last five years, Cash from Operations for AKBA reached as high as 33805000.0 in Q3 2022 and fell as low as 54679000.0 in Q4 2022.
• Historically, Cash from Operations has averaged 5318352.94 across 5 years, with a median of 7167000.0 in 2023.
• Across the five-year window, Cash from Operations plunged 377.38% in 2024 and soared 797.02% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 54679000.0 in 2022, then surged by 95.78% to 2308000.0 in 2023, then tumbled by 93.5% to 4466000.0 in 2024, then surged by 797.02% to 31129000.0 in 2025, then tumbled by 168.13% to 21207000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 21207000.0 in Q1 2026, 31129000.0 in Q4 2025, and 28105000.0 in Q3 2025.